Moreno-Martos et al., Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe, Wellcome Open Research, doi:10.12688/wellcomeopenres.17403.3
Aanlysis of prescriptions in multiple databases showing higher risk of COVID-19 hospitalization with acetaminophen use for COPD patients. Acetaminophen use was more prevalent in hospitalized patients compared to diagnosed patients (data from tables 1, 5, and S3).
Abstract: Wellcome Open Research 2023, 7:22 Last updated: 10 MAR 2023
RESEARCH ARTICLE
Characteristics and outcomes of COVID-19 patients with
COPD from the United States, South Korea, and Europe
[version 3; peer review: 2 approved]
David Moreno-Martos 1, Katia Verhamme2, Anna Ostropolets 3,
Kristin Kostka4,5, Talita Duarte-Sales6, Daniel Prieto-Alhambra7,
Thamir M Alshammari8, Heba Alghoul 9, Waheed-Ul-Rahman Ahmed7,10,
Clair Blacketer2,11, Scott DuVall12, Lana Lai13, Michael Matheny14,15,
Fredrik Nyberg 16, Jose Posada 17, Peter Rijnbeek2, Matthew Spotnitz 3,
Anthony Sena2,11, Nigam Shah17, Marc Suchard 18,19, Seng Chan You 20,
George Hripcsak3, Patrick Ryan3,11, Daniel Morales 1,21
1Population Health and Genomics, University of Dundee, Dundee, UK
2Medical Informatics, Erasmus MC, Rotterdam, The Netherlands
3Biomedical Informatics, Columbia University Medical Center, New York, USA
4Real World Solutions, IQVIA, Cambridge, MA, USA
5OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, USA
6Fundació Institut Universitari per a la recerca a l’Atenció Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), IDIAPJGol, Barcelona, Spain
7Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
8College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia
9Faculty of Medicine, Islamic University of Gaza, Gaza, Palestinian Territory
10College of Medicine and Health, University of Exeter, Exeter, UK
11Janssen Research and Development, Janssen Research and Development, Titusville, NJ, USA
12VA Informatics and Computing Infrastructure, University of Utah, Salt Lake City, UT, USA
13Department of Medical Sciences, University of Manchester, Manchester, UK
14Geriatrics Research Education and Clinical Care Service & VINCI, Tennessee Valley Healthcare System VA, nashville, TN, USA
15Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA
16School of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden
17Department of Medicine, Stanford University, Redwood City, CA, USA
18Department of Biostatistics UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA
19Department of Computational Medicine David Geffen School of Medicine at UCLA,, University of California, Los Angeles, Los
Angeles, CA, USA
20Department of Preventive Medicine, Yonsei University, Seoul, South Korea
21Department of Public Health, University of Southern Denmark, Odense, Denmark
v3 First published: 24 Jan 2022, 7:22
https://doi.org/10.12688/wellcomeopenres.17403.1
Second version: 24 Mar 2022, 7:22
https://doi.org/10.12688/wellcomeopenres.17403.2
Open Peer Review
Approval Status
Latest published: 10 Jan 2023, 7:22
https://doi.org/10.12688/wellcomeopenres.17403.3
1
2
version 3
Abstract
Background: Characterization studies of COVID-19 patients with
view
Page 1 of 25
Wellcome Open Research 2023, 7:22 Last updated: 10 MAR 2023
chronic obstructive pulmonary disease (COPD) are limited in size and
scope. The aim of the study is to provide a large-scale characterization
of COVID-19 patients with COPD.
Methods: We included thirteen databases contributing data from
January-June 2020 from North America (US), Europe and Asia. We
defined two cohorts of patients with COVID-19 namely a ‘diagnosed’
and ‘hospitalized’ cohort. We followed patients from COVID-19 index
date to 30 days or death. We performed..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.